Agenus Company Profile (NASDAQ:AGEN)

About Agenus (NASDAQ:AGEN)

Agenus logoAgenus Inc. (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company's discovery pipeline includes a range of checkpoint modulating (CPM) antibodies. The Company's vaccine platforms include its heat shock protein (HSP)-based Prophage vaccine candidates, and its synthetic vaccine candidates, ASV and PSV.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:AGEN
  • CUSIP: 00847G70
  • Web: www.agenusbio.com
Capitalization:
  • Market Cap: $408.82 million
  • Outstanding Shares: 99,712,000
Average Prices:
  • 50 Day Moving Avg: $3.84
  • 200 Day Moving Avg: $3.85
  • 52 Week Range: $3.20 - $7.49
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.11
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $41.19 million
  • Price / Sales: 9.93
  • Book Value: ($0.18) per share
  • Price / Book: -22.78
Profitability:
  • EBIDTA: ($92,050,000.00)
  • Net Margins: -280.96%
  • Return on Equity: -37,577.49%
  • Return on Assets: -65.05%
Debt:
  • Debt-to-Equity Ratio: -7.93%
  • Current Ratio: 3.36%
  • Quick Ratio: 3.36%
Misc:
  • Average Volume: 1.11 million shs.
  • Beta: 2.1
  • Short Ratio: 7.7
 

Frequently Asked Questions for Agenus (NASDAQ:AGEN)

What is Agenus' stock symbol?

Agenus trades on the NASDAQ under the ticker symbol "AGEN."

How were Agenus' earnings last quarter?

Agenus Inc. (NASDAQ:AGEN) announced its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.04. The business had revenue of $4.21 million for the quarter, compared to analyst estimates of $6.66 million. Agenus had a negative return on equity of 37,577.49% and a negative net margin of 280.96%. The company's quarterly revenue was down 36.1% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.33) earnings per share. View Agenus' Earnings History.

When will Agenus make its next earnings announcement?

Agenus is scheduled to release their next quarterly earnings announcement on Thursday, October, 26th 2017. View Earnings Estimates for Agenus.

Where is Agenus' stock going? Where will Agenus' stock price be in 2017?

4 brokerages have issued 12-month price objectives for Agenus' stock. Their predictions range from $5.00 to $7.00. On average, they anticipate Agenus' stock price to reach $6.33 in the next twelve months. View Analyst Ratings for Agenus.

Who are some of Agenus' key competitors?

Who are Agenus' key executives?

Agenus' management team includes the folowing people:

  • Garo H. Armen Ph.D., Chairman of the Board, Chief Executive Officer, Founder
  • Christine M. Klaskin, Vice President - Finance
  • Karen Higgins Valentine, General Counsel, Chief Legal Officer
  • Ozer Baysal, Chief Commercial Officer, Head of HR
  • Jean-Marie Cuillerot M.D., Chief Medical Officer
  • Brian Corvese, Independent Director
  • Wadih Jordan, Independent Director
  • Shalini Sharp, Independent Director
  • Ulf Wiinberg, Independent Director
  • Timothy R. Wright, Independent Director

Who owns Agenus stock?

Agenus' stock is owned by a number of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.56%), Artal Group S.A. (2.02%), FMR LLC (1.50%), State Street Corp (1.40%), Northern Trust Corp (0.95%) and Candriam Luxembourg S.C.A. (0.55%). Company insiders that own Agenus stock include Charles Evan Ballantyne, Corp Incyte, Garo H Armen, Ozer Baysal and Ulf Wiinberg. View Institutional Ownership Trends for Agenus.

Who sold Agenus stock? Who is selling Agenus stock?

Agenus' stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Artal Group S.A., Chicago Equity Partners LLC, Bank of New York Mellon Corp, Virtu KCG Holdings LLC, FMR LLC, California State Teachers Retirement System and Schwab Charles Investment Management Inc.. View Insider Buying and Selling for Agenus.

Who bought Agenus stock? Who is buying Agenus stock?

Agenus' stock was bought by a variety of institutional investors in the last quarter, including Spark Investment Management LLC, Vanguard Group Inc., Captrust Financial Advisors, Wells Fargo & Company MN, State of Wisconsin Investment Board, Northern Trust Corp, OxFORD Asset Management LLP and Alliancebernstein L.P.. Company insiders that have bought Agenus stock in the last two years include Charles Evan Ballantyne, Corp Incyte, Garo H Armen, Ozer Baysal and Ulf Wiinberg. View Insider Buying and Selling for Agenus.

How do I buy Agenus stock?

Shares of Agenus can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Agenus' stock price today?

One share of Agenus stock can currently be purchased for approximately $4.10.


MarketBeat Community Rating for Agenus (NASDAQ AGEN)
Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  204 (Vote Outperform)
Underperform Votes:  86 (Vote Underperform)
Total Votes:  290
MarketBeat's community ratings are surveys of what our community members think about Agenus and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Agenus (NASDAQ:AGEN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $6.33 (54.47% upside)

Analysts' Ratings History for Agenus (NASDAQ:AGEN)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/4/2017Jefferies Group LLCReiterated RatingBuy$7.00HighView Rating Details
5/6/2017HC WainwrightSet Price TargetHold$5.00LowView Rating Details
4/23/2017Maxim GroupReiterated RatingBuy$7.00MediumView Rating Details
12/1/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
3/9/2016J P Morgan Chase & CoLower Price TargetMarket Outperform$17.00 -> $15.00N/AView Rating Details
12/31/2015Oppenheimer Holdings, Inc.Reiterated RatingPositive -> Outperform$14.00N/AView Rating Details
(Data available from 9/25/2015 forward)

Earnings

Earnings History for Agenus (NASDAQ:AGEN)
Earnings by Quarter for Agenus (NASDAQ:AGEN)
Earnings History by Quarter for Agenus (NASDAQ AGEN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/26/2017        
8/3/2017Q2 2017($0.36)($0.32)$6.66 million$4.21 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.32)($0.18)$5.22 million$26.96 millionViewListenView Earnings Details
3/9/2017Q4 2016($0.30)($0.30)$6.01 million$5.58 millionViewListenView Earnings Details
10/27/2016Q316($0.32)($0.47)$6.15 million$4.45 millionViewListenView Earnings Details
7/28/2016Q216($0.34)($0.33)$5.12 million$6.59 millionViewListenView Earnings Details
4/28/2016Q116($0.23)($0.37)$6.74 million$5.96 millionViewListenView Earnings Details
3/3/2016Q415($0.17)($0.18)$9.39 million$7.64 millionViewListenView Earnings Details
10/27/2015Q315($0.15)($0.16)$5.71 million$6.85 millionViewListenView Earnings Details
7/23/2015Q215($0.15)($0.44)$5.71 million$6.38 millionViewListenView Earnings Details
4/23/2015Q115($0.15)($0.21)$11.66 million$3.95 millionViewN/AView Earnings Details
2/26/2015Q414($0.15)($0.18)$0.66 million$1.62 millionViewN/AView Earnings Details
10/31/2014Q314($0.15)($0.13)$1.96 million$1.56 millionViewN/AView Earnings Details
7/24/2014Q214($0.11)($0.12)$0.71 million$3.07 millionViewN/AView Earnings Details
5/8/2014Q114($0.16)$0.01$0.55 million$0.72 millionViewN/AView Earnings Details
3/5/2014Q413($0.24)($0.16)$870.00 million$393.00 millionViewN/AView Earnings Details
10/24/2013Q313($0.27)($0.24)$736.00 millionViewN/AView Earnings Details
7/25/2013Q2 2013($0.21)($0.40)ViewN/AView Earnings Details
2/28/2013Q4 2012($0.24)($0.23)$0.72 million$1.09 millionViewN/AView Earnings Details
7/28/2011($0.05)($0.05)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Agenus (NASDAQ:AGEN)
2017 EPS Consensus Estimate: ($1.28)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.33)($0.24)($0.29)
Q2 20172($0.34)($0.30)($0.32)
Q3 20172($0.34)($0.31)($0.33)
Q4 20171($0.35)($0.35)($0.35)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Agenus (NASDAQ:AGEN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Agenus (NASDAQ:AGEN)
Insider Ownership Percentage: 7.90%
Institutional Ownership Percentage: 39.51%
Insider Trades by Quarter for Agenus (NASDAQ:AGEN)
Institutional Ownership by Quarter for Agenus (NASDAQ:AGEN)
Insider Trades by Quarter for Agenus (NASDAQ:AGEN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/12/2017Garo H ArmenCEOBuy100,000$3.35$335,000.00View SEC Filing  
2/14/2017Corp IncyteMajor ShareholderBuy10,000,000$6.00$60,000,000.00View SEC Filing  
9/6/2016Ulf WiinbergDirectorBuy30,000$6.29$188,700.00View SEC Filing  
5/9/2016Garo H ArmenCEOBuy100,000$3.18$318,000.00View SEC Filing  
5/5/2016Ozer BaysalInsiderBuy2,250$3.10$6,975.00View SEC Filing  
3/7/2016Garo H ArmenCEOBuy200,000$4.03$806,000.00View SEC Filing  
12/29/2015Garo H. ArmenCEOSell219,576$4.59$1,007,853.84View SEC Filing  
12/28/2015Garo H. ArmenCEOSell134,352$4.60$618,019.20View SEC Filing  
9/25/2015Charles Evan BallantyneCFOBuy10,000$5.05$50,500.00View SEC Filing  
9/25/2015Garo H ArmenCEOBuy100,000$5.03$503,000.00View SEC Filing  
4/29/2015Shahzad MalikDirectorSell1,107,377$7.11$7,873,450.47View SEC Filing  
1/9/2015Qvt Associates Gp LlcMajor ShareholderSell2,343,630$5.31$12,444,675.30View SEC Filing  
1/23/2014Karen ValentineVPSell2,850$3.50$9,975.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Agenus (NASDAQ:AGEN)
Latest Headlines for Agenus (NASDAQ:AGEN)
Source:
DateHeadline
americanbankingnews.com logoAgenus Inc. (AGEN) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - September 23 at 2:44 AM
finance.yahoo.com logoAgenus, Inc. breached its 50 day moving average in a Bearish Manner : AGEN-US : September 22, 2017
finance.yahoo.com - September 22 at 2:54 PM
prnewswire.com logoAgenus to Present at Two Healthcare Investor Conferences In September - PR Newswire (press release)
www.prnewswire.com - September 19 at 3:38 PM
finance.yahoo.com logoAgenus to Present at Two Healthcare Investor Conferences In September
finance.yahoo.com - September 19 at 3:38 PM
americanbankingnews.com logoZacks: Brokerages Expect Agenus Inc. (AGEN) Will Announce Quarterly Sales of $5.37 Million
www.americanbankingnews.com - September 19 at 6:02 AM
americanbankingnews.com logoArbutus Biopharma Corporation (ABUS) versus Agenus (AGEN) Critical Analysis
www.americanbankingnews.com - September 18 at 2:50 PM
americanbankingnews.com logoZacks: Brokerages Anticipate Agenus Inc. (AGEN) to Announce -$0.37 Earnings Per Share
www.americanbankingnews.com - September 17 at 4:44 PM
nasdaq.com logoAnother 'Picks And Shovels' Nasdaq Stock With Massive Potential
www.nasdaq.com - September 15 at 1:55 AM
prnewswire.com logoGSK's Shingrix containing Agenus' QS-21 Stimulon® adjuvant receives Unanimous FDA Advisory Committee ... - PR Newswire (press release)
www.prnewswire.com - September 13 at 9:43 PM
finance.yahoo.com logoBefore You Buy Agenus Inc’s (AGEN), You Should Consider This
finance.yahoo.com - September 13 at 4:40 PM
finance.yahoo.com logoFDA Advisory Committee votes unanimously for Shingrix (HZ/su) in the US for prevention of herpes zoster (shingles) in adults ages 50 and over
finance.yahoo.com - September 13 at 4:40 PM
finance.yahoo.com logo'Impressed' FDA panel unanimously recommends GSK shingles vaccine
finance.yahoo.com - September 13 at 4:40 PM
finance.yahoo.com logoGSK's Shingrix containing Agenus' QS-21 Stimulon® adjuvant receives Unanimous FDA Advisory Committee recommendation for approval
finance.yahoo.com - September 13 at 4:40 PM
finance.yahoo.com logoETFs with exposure to Agenus, Inc. : September 12, 2017
finance.yahoo.com - September 11 at 9:27 PM
finance.yahoo.com logoAgenus, Inc. breached its 50 day moving average in a Bullish Manner : AGEN-US : September 11, 2017
finance.yahoo.com - September 11 at 4:23 PM
americanbankingnews.com logoAgenus Inc. (AGEN) Upgraded by ValuEngine to "Sell"
www.americanbankingnews.com - September 9 at 11:58 PM
nasdaq.com logoWhy Is Agenus (AGEN) Down 11.8% Since the Last Earnings Report? - Nasdaq
www.nasdaq.com - September 5 at 9:37 PM
finance.yahoo.com logoWhy Is Agenus (AGEN) Down 11.8% Since the Last Earnings Report?
finance.yahoo.com - September 5 at 4:34 PM
americanbankingnews.com logo$5.37 Million in Sales Expected for Agenus Inc. (AGEN) This Quarter
www.americanbankingnews.com - September 1 at 8:42 AM
finance.yahoo.com logoETFs with exposure to Agenus, Inc. : August 31, 2017
finance.yahoo.com - August 31 at 8:33 PM
americanbankingnews.com logoZacks: Analysts Expect Agenus Inc. (AGEN) to Announce -$0.36 EPS
www.americanbankingnews.com - August 30 at 4:06 AM
americanbankingnews.com logoAgenus Inc. (AGEN) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - August 29 at 2:34 AM
finance.yahoo.com logoAgenus, Inc. :AGEN-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017
finance.yahoo.com - August 25 at 5:12 PM
americanbankingnews.com logoZacks Investment Research Lowers Agenus Inc. (AGEN) to Hold
www.americanbankingnews.com - August 25 at 2:22 PM
fool.com logo3 Top Biotech Stocks Under $5 - Motley Fool
www.fool.com - August 19 at 3:26 PM
fool.com logo3 Top Biotech Stocks Under $5 - Motley Fool
www.fool.com - August 19 at 3:26 PM
finance.yahoo.com logoAgenus, Inc. – Value Analysis (NASDAQ:AGEN) : August 18, 2017
finance.yahoo.com - August 18 at 8:50 PM
finance.yahoo.com logoAgenus, Inc. breached its 50 day moving average in a Bearish Manner : AGEN-US : August 7, 2017
finance.yahoo.com - August 7 at 4:31 PM
americanbankingnews.com logoAgenus Inc. (NASDAQ:AGEN) Given Buy Rating at Jefferies Group LLC
www.americanbankingnews.com - August 6 at 12:34 AM
fool.com logoHere's Why Agenus Inc. Stock Slipped 13.6% in July - Motley Fool
www.fool.com - August 4 at 9:08 PM
finance.yahoo.com logoEdited Transcript of AGEN earnings conference call or presentation 3-Aug-17 3:00pm GMT
finance.yahoo.com - August 4 at 9:08 PM
finance.yahoo.com logoHere's Why Agenus Inc. Stock Slipped 13.6% in July
finance.yahoo.com - August 4 at 9:08 PM
fool.com logoHere's Why Agenus Inc. Stock Slipped 13.6% in July
www.fool.com - August 4 at 6:15 PM
finance.yahoo.com logoAgenus (AGEN) Q2 Loss Narrower Than Expected, Revenues Lag
finance.yahoo.com - August 4 at 3:59 PM
americanbankingnews.com logoAgenus Inc. (AGEN) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - August 4 at 7:44 AM
finance.yahoo.com logoAgenus Reports Second Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - August 3 at 4:40 PM
streetinsider.com logoForm 8-K AGENUS INC For: Aug 03 - StreetInsider.com
www.streetinsider.com - August 3 at 4:40 PM
finance.yahoo.com logoSucampo (SCMP) Q2 Earnings & Revenues Beat Estimates, Up Y/Y
finance.yahoo.com - August 3 at 4:40 PM
finance.yahoo.com logoSucampo (SCMP) Q2 Earnings & Revenues Beat Estimates, Up Y/Y
finance.yahoo.com - August 3 at 4:40 PM
finance.yahoo.com logoAgenus (AGEN) Reports Narrower-than-Expected Q2 Loss
finance.yahoo.com - August 3 at 4:40 PM
finance.yahoo.com logoAgenus (AGEN) Reports Narrower-than-Expected Q2 Loss
finance.yahoo.com - August 3 at 4:40 PM
finance.yahoo.com logoAgenus reports 2Q loss
finance.yahoo.com - August 3 at 4:40 PM
finance.yahoo.com logoAgenus reports 2Q loss
finance.yahoo.com - August 3 at 4:40 PM
americanbankingnews.com logoAgenus Inc. (AGEN) Releases Quarterly Earnings Results, Beats Estimates By $0.04 EPS
www.americanbankingnews.com - August 3 at 3:38 PM
prnewswire.com logoAgenus to Report Second Quarter 2017 Financial Results on August 3, 2017; Conference Call to Follow - PR Newswire (press release)
www.prnewswire.com - July 27 at 3:48 PM
americanbankingnews.com logoZacks: Brokerages Expect Agenus Inc. (AGEN) Will Announce Quarterly Sales of $6.49 Million
www.americanbankingnews.com - July 26 at 1:00 PM
finance.yahoo.com logoIs a Beat in Store for Agenus (AGEN) this Earnings Season?
finance.yahoo.com - July 24 at 1:40 PM
americanbankingnews.com logo Brokerages Expect Agenus Inc. (NASDAQ:AGEN) Will Post Earnings of -$0.36 Per Share
www.americanbankingnews.com - July 24 at 12:36 PM
nasdaq.com logoIs a Beat in Store for Alexion (ALXN) this Earnings Season?
www.nasdaq.com - July 20 at 4:16 PM
finance.yahoo.com logouniQure N.V. (QURE) Shows Strength: Stock Moves 9.1% Higher
finance.yahoo.com - July 20 at 4:16 PM

Social

Chart

Agenus (AGEN) Chart for Monday, September, 25, 2017

This page was last updated on 9/25/2017 by MarketBeat.com Staff